Neuroscientific Biopharmaceuticals (ASX:NSB) Long-Term Debt: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neuroscientific Biopharmaceuticals Long-Term Debt?

Neuroscientific Biopharmaceuticals ASX:NSB Long-Term Debt is A$0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Neuroscientific Biopharmaceuticals's Long-Term Debt for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Neuroscientific Biopharmaceuticals  (ASX:NSB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Neuroscientific Biopharmaceuticals Long-Term Debt Related Terms

Neuroscientific Biopharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Neuroscientific Biopharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuroscientific Biopharmaceuticals Long-Term Debt Chart

Neuroscientific Biopharmaceuticals Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Neuroscientific Biopharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of A$0.00 Mil mean?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a Long-Term Debt of A$0.00 Mil as of Dec. 2025.
Is Neuroscientific Biopharmaceuticals' Long-Term Debt too high?
Neuroscientific Biopharmaceuticals' current Long-Term Debt is A$0.00 Mil.
How does Neuroscientific Biopharmaceuticals' Long-Term Debt compare to VRTX and REGN?
Neuroscientific Biopharmaceuticals' Long-Term Debt of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Neuroscientific Biopharmaceuticals's current Long-Term Debt is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuroscientific Biopharmaceuticals stock overvalued right now?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a current Long-Term Debt of A$0.00 Mil. The current Long-Term Debt is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Neuroscientific Biopharmaceuticals (ASX:NSB), the current Long-Term Debt is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuroscientific Biopharmaceuticals Business Description

Address 216 Street Georges Terrace, Level 4, Perth, WA, AUS, 6000
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and treatments for neurodegenerative diseases through preclinical studies of patented technologies.